[go: up one dir, main page]

CO2018008450A2 - Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano - Google Patents

Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano

Info

Publication number
CO2018008450A2
CO2018008450A2 CONC2018/0008450A CO2018008450A CO2018008450A2 CO 2018008450 A2 CO2018008450 A2 CO 2018008450A2 CO 2018008450 A CO2018008450 A CO 2018008450A CO 2018008450 A2 CO2018008450 A2 CO 2018008450A2
Authority
CO
Colombia
Prior art keywords
diaza
decane
spiro
oxo
derivatives
Prior art date
Application number
CONC2018/0008450A
Other languages
English (en)
Inventor
Achim Kless
Sven Kühnert
René Michael Koenigs
Anita Wegert
Paul Ratcliffe
Ruth Jostock
Thomas Koch
Klaus Linz
Wolfgang Schröder
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of CO2018008450A2 publication Critical patent/CO2018008450A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano, su preparación y su uso en medicamentos, en particular en el tratamiento del dolor.
CONC2018/0008450A 2016-01-13 2017-01-13 Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano CO2018008450A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16151015 2016-01-13
PCT/EP2017/025008 WO2017121650A1 (en) 2016-01-13 2017-01-13 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Publications (1)

Publication Number Publication Date
CO2018008450A2 true CO2018008450A2 (es) 2018-09-20

Family

ID=55129636

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0008450A CO2018008450A2 (es) 2016-01-13 2017-01-13 Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano

Country Status (26)

Country Link
US (7) US20170197949A1 (es)
EP (1) EP3402782B1 (es)
JP (1) JP6917379B2 (es)
KR (1) KR20180097734A (es)
CN (1) CN108602778B (es)
AR (1) AR107359A1 (es)
AU (1) AU2017206911B2 (es)
BR (1) BR112018014301B1 (es)
CA (1) CA3011182A1 (es)
CL (1) CL2018001909A1 (es)
CO (1) CO2018008450A2 (es)
CY (1) CY1123366T1 (es)
DK (1) DK3402782T3 (es)
EA (1) EA034898B1 (es)
EC (1) ECSP18060875A (es)
ES (1) ES2821969T3 (es)
HR (1) HRP20201660T1 (es)
HU (1) HUE051642T2 (es)
IL (1) IL260488B (es)
LT (1) LT3402782T (es)
MX (1) MX379359B (es)
PT (1) PT3402782T (es)
RS (1) RS60855B1 (es)
SI (1) SI3402782T1 (es)
TW (1) TWI654181B (es)
WO (1) WO2017121650A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017206909B2 (en) 2016-01-13 2020-07-09 Grünenthal GmbH 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US20170197971A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
TWI635082B (zh) 2016-01-13 2018-09-11 歌林達有限公司 ３－（（雜－）芳基）－８－胺基－２－側氧－１,３－二氮雜－螺－［４.５］－癸烷衍生物
SI3402783T1 (sl) 2016-01-13 2020-10-30 Gruenenthal Gmbh Derivati 3-(karboksietil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
CO2018008450A2 (es) 2016-01-13 2018-09-20 Gruenenthal Gmbh Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
WO2019039852A1 (ko) 2017-08-22 2019-02-28 주식회사 엘지화학 방열 소재 디스펜싱 장치의 결정방법
TWI827785B (zh) 2019-01-11 2024-01-01 德商歌林達有限公司 經取代的吡咯啶醯胺iii
CN110092790B (zh) * 2019-06-11 2020-07-24 东北农业大学 一种生物碱类化合物及其制备方法和应用
US20240400537A1 (en) 2023-04-25 2024-12-05 Gruenenthal Gmbh Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
BR0209128A (pt) 2001-04-18 2005-11-01 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10135636A1 (de) * 2001-07-17 2003-02-06 Gruenenthal Gmbh Substituierte 4-Aminocyclohexanole
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
CA2491506C (en) 2002-07-05 2011-04-26 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2532059A1 (en) 2003-05-23 2004-12-02 Zealand Pharma A/S Triaza-spiro compounds as nociceptin analogues and uses thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
KR101118410B1 (ko) 2006-10-19 2012-04-23 에프. 호프만-라 로슈 아게 당뇨병을 위한 11베타-에이치에스디1 억제제로서의 이미다졸론 및 이미다졸리딘온 유도체
MX2009011006A (es) 2007-04-09 2009-11-02 Janssen Pharmaceutica Nv Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion.
AU2009228642B2 (en) 2008-03-27 2013-11-07 Grunenthal Gmbh Substituted 4-aminocyclohexane derivatives
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
US8268853B2 (en) 2009-06-25 2012-09-18 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
JP6643545B2 (ja) * 2014-03-14 2020-02-12 ラクオリア創薬株式会社 Ｔｒｐｍ８拮抗剤としてのアザスピロ誘導体
WO2015192039A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
TWI635082B (zh) 2016-01-13 2018-09-11 歌林達有限公司 ３－（（雜－）芳基）－８－胺基－２－側氧－１,３－二氮雜－螺－［４.５］－癸烷衍生物
UY37073A (es) 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
SI3402783T1 (sl) 2016-01-13 2020-10-30 Gruenenthal Gmbh Derivati 3-(karboksietil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
CO2018008450A2 (es) 2016-01-13 2018-09-20 Gruenenthal Gmbh Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
US20170197971A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
AU2017206909B2 (en) 2016-01-13 2020-07-09 Grünenthal GmbH 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
RU2747877C2 (ru) 2016-01-13 2021-05-17 Ново Нордиск А/С Аналоги эфр(а) с заместителями - жирными кислотами

Also Published As

Publication number Publication date
TWI654181B (zh) 2019-03-21
WO2017121650A1 (en) 2017-07-20
MX2018008645A (es) 2018-11-19
HUE051642T2 (hu) 2021-03-01
US20180273516A1 (en) 2018-09-27
CL2018001909A1 (es) 2018-10-19
US20190375738A1 (en) 2019-12-12
ES2821969T3 (es) 2021-04-28
EP3402782B1 (en) 2020-07-29
DK3402782T3 (da) 2020-09-28
CA3011182A1 (en) 2017-07-20
TW201730155A (zh) 2017-09-01
BR112018014301B1 (pt) 2023-10-31
ECSP18060875A (es) 2018-08-31
US20190100515A1 (en) 2019-04-04
JP6917379B2 (ja) 2021-08-11
AU2017206911B2 (en) 2020-07-09
US20200399255A1 (en) 2020-12-24
HRP20201660T1 (hr) 2021-03-05
MX379359B (es) 2025-03-11
JP2019501932A (ja) 2019-01-24
US10793556B2 (en) 2020-10-06
EA201891608A1 (ru) 2019-01-31
CY1123366T1 (el) 2021-12-31
RS60855B1 (sr) 2020-10-30
IL260488B (en) 2021-09-30
NZ745186A (en) 2024-05-31
LT3402782T (lt) 2020-10-12
AU2017206911A1 (en) 2018-08-30
AR107359A1 (es) 2018-04-25
US20210179595A1 (en) 2021-06-17
PT3402782T (pt) 2020-10-01
US20170197949A1 (en) 2017-07-13
US20230183222A1 (en) 2023-06-15
EP3402782A1 (en) 2018-11-21
SI3402782T1 (sl) 2020-11-30
EA034898B1 (ru) 2020-04-03
CN108602778A (zh) 2018-09-28
CN108602778B (zh) 2021-12-10
KR20180097734A (ko) 2018-08-31
BR112018014301A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
ECSP18060848A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[ 4.5]-decano
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CO2017001994A2 (es) Compuestos activos hacia bromodominios
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
ECSP18060834A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2018002368A1 (es) Formulaciones de oritavancina
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
MX2018012223A (es) Formulaciones liquidas de fosfaplatino.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.